ImmunityBio, Inc. (IBRX) Institutional Ownership

Ownership Summary

Recent 13F filings as of September 2025 show that 259 institutional investors hold a position in ImmunityBio, Inc. (NASDAQ:IBRX).

• The collective stake of institutional investors in ImmunityBio moved to 15.9% in September 2025, a shift up from the 14.1% reported for June 2025.
• The company experienced a 28.11% quarterly change in institutional shares held, alongside an increase of 44.69% in total owners annually.
• A review of institutional activity for ImmunityBio shows 130 of 259 filers increasing their positions, while 63 reduced their stake, and 66 remained unchanged.
• Collectively, institutional investors increased their stake in ImmunityBio to 150.47Mn shares as of September 2025, a change that is up by 33.02Mn shares quarter on quarter and up 81.00Mn shares year over year.
• The top institutional stake in ImmunityBio as of September 30, 2025 belongs to VANGUARD GROUP INC, which owns 27.66Mn shares, or 2.93% of the company.
• Among the most significant buyers of ImmunityBio during September 2025 were HEIGHTS CAPITAL MANAGEMENT, INC (13.13Mn), VANGUARD GROUP INC (5.84Mn), JANE STREET GROUP, LLC (5.05Mn), STATE STREET CORP (3.70Mn), BlackRock, Inc. (2.04Mn).
• Leading sellers of ImmunityBio stock in September 2025 included BANK OF AMERICA CORP /DE/ (7.10Mn), MILLENNIUM MANAGEMENT LLC (3.20Mn), UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (358.97K), ROYAL BANK OF CANADA (344.68K), FIRST TRUST ADVISORS LP (276.67K).
• The top 10 institutional holders of ImmunityBio for the quarter ending September 2025 included VANGUARD GROUP INC (27.66Mn), BlackRock, Inc. (19.81Mn), JANE STREET GROUP, LLC (13.45Mn), HEIGHTS CAPITAL MANAGEMENT, INC (13.13Mn), STATE STREET CORP (11.32Mn), GEODE CAPITAL MANAGEMENT, LLC (6.89Mn), Woodline Partners LP (5.30Mn), MORGAN STANLEY (3.37Mn), AlphaCore Capital LLC (2.99Mn), SUSQUEHANNA INTERNATIONAL GROUP, LLP (2.64Mn).